CytoSorbents (CytoSorbents) Total Inventories : $3.74 Mil (As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is CytoSorbents Total Inventories?

CytoSorbents's total inventories for the quarter that ended in Mar. 2024 was $3.74 Mil. CytoSorbents's average total inventories from the quarter that ended in Dec. 2023 to the quarter that ended in Mar. 2024 was $3.71 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. CytoSorbents's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $-0.23.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. CytoSorbents's Days Inventory for the three months ended in Mar. 2024 was 105.25.

Inventory Turnover measures how fast the company turns over its inventory within a year. CytoSorbents's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.87.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. CytoSorbents's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.41.

CytoSorbents Total Inventories Historical Data

The historical data trend for CytoSorbents's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoSorbents Total Inventories Chart

CytoSorbents Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

2.11

2.67

4.77

3.46

3.68

CytoSorbents Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Inventories	Get a 7-Day Free Trial															1.73	2.05	2.98	3.68	3.74

CytoSorbents Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

CytoSorbents (NAS:CTSO) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

CytoSorbents's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is

	Net-Net Working Capital Per Share (Q: Mar. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(8.608	+	0.75 * 6.765	+	0.5 * 3.739	-	28.143
-	0	-	0)	/	54.2936
=	-0.23

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

CytoSorbents's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2024 )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
	=	3.7095	/	3.216	*	365 / 4
	=	105.25

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

CytoSorbents's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2024 )	/	Average Total Inventories (Q: Mar. 2024 )
	=	3.216	/	3.7095
	=	0.87

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

CytoSorbents's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	3.7095	/	8.99
	=	0.41

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

CytoSorbents Total Inventories Related Terms

Thank you for viewing the detailed overview of CytoSorbents's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoSorbents (CytoSorbents) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CytoSorbents Corp (NAS:CTSO) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

HQE1:Germany

Address

305 College Road East, Princeton, NJ, USA, 08540

Website

https://www.cytosorbents.com

CytoSorbents Corp is involves in the treatment of life-threatening conditions in the intensive care (ICU) and cardiac surgery using blood purification via proprietary polymer adsorption technology. It has a number of products commercialized and in development based on this technology platform.

Executives

Edward Raymond Jones	director	70 HOGAN LANE, AMBLER PA 19002
Kathleen P. Bloch	officer: Chief Financial Officer	3 PERSHING COURT, NORTH BRUNSWICK NJ 08902
Vincent Capponi	officer: Chief Operating Officer	MEDASORB TECHNOLOGIES, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Phillip P. Chan	director, officer: President and CEO	1001 BRIGGS ROAD, SUITE 280, MOUNT LAUREL NJ 08054
Efthymios Deliargyris	officer: Chief Medical Officer	C/O PLX PHARMA,INC.8285 EL RIO STREET, SUITE 210, HOUSTON TX 77054
Jiny Kim	director	C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Alan D. Sobel	director	293 EISENHOWER PARKWAY, LIVINGSTON NJ 07039
Michael G. Bator	director	C/O CYTOSORBENTS CORP., 7 DEER PARK DR., SUITE K, MONMOUTH JUNCTION NJ 08852
Alex D'amico	officer: Chief Financial Officer	10 EAST PASSAIC AVENUE, UNIT C-2, NUTLEY NJ 07110
Al Kraus	director	MEDASORB TECHNOLOGIES, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Eric R. Mortensen	officer: Chief Medical Officer	C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Njtc Investment Fund, Lp	10 percent owner	1001 BRIGGS ROAD, SUITE 280, MOUNT LAUREL NJ 08054
Robert Shipley	10 percent owner	9 NOBLE ROAD, NOGALES AZ 85621
Ronald Berger	officer: See Remarks	7 DEERPARK DRIVE, STE K, MONMOUTH JUNCTION NJ 08852
Thomas Bocchino	officer: Chief Financial Officer	C/O CYTOSORBENTS CORP., 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852